These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21114416)

  • 1. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
    Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
    Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
    DeGorter MK; Urquhart BL; Gradhand U; Tirona RG; Kim RB
    J Clin Pharmacol; 2012 Nov; 52(11):1689-97. PubMed ID: 22167570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
    Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
    Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
    Sanwald-Ducray P; Jamois C; Banken L
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
    Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
    Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
    Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
    Knauer MJ; Urquhart BL; Meyer zu Schwabedissen HE; Schwarz UI; Lemke CJ; Leake BF; Kim RB; Tirona RG
    Circ Res; 2010 Feb; 106(2):297-306. PubMed ID: 19940267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.
    Son H; Roh H; Lee D; Chang H; Kim J; Yun C; Park K
    Clin Ther; 2013 Jul; 35(7):915-22. PubMed ID: 23810276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
    Derks M; Abt M; Parr G; Meneses-Lorente G; Young AM; Phelan M
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1135-45. PubMed ID: 20738227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
    Trabelsi F; Bartůnek A; Vlavonou R; Navrátilová L; Dubé C; Tanguay M; Hauser T
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):741-50. PubMed ID: 22762855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
    Rahalkar AR; Ban MR; Hegele RA
    Can J Cardiol; 2013 Apr; 29(4):418-22. PubMed ID: 22840301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
    Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
    J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.